Central nervous system adverse effects of new antiepileptic drugs. A meta-analysis of placebo-controlled studies

Seizure

Volumn 17, Issue 5, 2008, Pages 405-421

  Zaccara, G ^a   Gangemi, P F ^b   Cincotta, M ^a  

^a SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^b Anffas Rehabilitation Institute   (Italy)

Author keywords

Antiepileptic drugs; Gabapentin; Lamotrigine; Levetiracetam; Meta analysis; Oxcarbazepine; Tiagabine; Topiramate; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; PREGABALIN; TIAGABINE; TOPIRAMATE; ZONISAMIDE;

ANXIETY; ARTICLE; ATAXIA; ATTRIBUTABLE RISK; BEHAVIOR DISORDER; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIPLOPIA; DIZZINESS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; EPILEPSY; FATIGUE; HEADACHE; HUMAN; MENTAL DISEASE; META ANALYSIS; NYSTAGMUS; PRIORITY JOURNAL; PSYCHOSIS; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREMOR; VERTIGO;

ANTICONVULSANTS; CENTRAL NERVOUS SYSTEM; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; EPILEPSY; HUMANS; MEDLINE; ODDS RATIO; PERIODICALS AS TOPIC;

EID: 44749089243     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.seizure.2007.12.003     Document Type: Article

References (56)

1. Otoul C., Arrigo C., van Rijckevorsel K., and French J.A. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 28 (2005) 72-78
2. Perucca E. Clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 15 (2001) 405-417
3. Marson A.G., Kadir Z.A., Hutton J.L., and Chadwick D.W. The new antiepileptic drugs: asystematic review of their efficacy and tolerability. Epilepsia 38 (1997) 859-880
4. Marson A.G., Hutton J.L., Leach J.P., Castillo S., Schmidt D., White S., et al. Levetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. Epilepsy Res 46 (2001) 259-270
5. Cramer J.A., Fisher R., Ben-Menachem E., French J., and Mattson R.H. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40 (1999) 590-600
6. Cramer J.A., Ben-Menachem E., and French J. Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation. Epilepsy Res 47 (2001) 17-25
7. Guberman A., Neto W., Gassmann-Mayer C., and EPAJ-119 Study Group. Low-dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 106 4 (2002) 183-189
8. French J.A., Kugler A.R., Robbins J.L., Knapp L.E., and Garofalo E.A. Dose-response trial of pregabalin adjunctive therapy in patients with partial seizures. Neurology 60 (2003) 1631-1637
9. Arroyo S., et al. Pregabalin add-on treatment: a randomized, double-blind, placebo-controlled, dose-response study in adults with partial seizures. Epilepsia 45 (2004) 20-27
10. Beydoun A., Uthman B.M., Kugler A.R., Greiner M.J., Knapp L.E., Garofalo E.A., and Pregabalin 1008-009 Study Group. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy. Neurology 64 (2005) 475-480
11. Brodie M.J., Duncan R., Vespignani H., Solyom A., Bitenskyy V., and Lucas C. Dose-dependent safety and efficacy of zonisamide: a randomized, double-blind, placebo-controlled study in patients with refractory partial seizures. Epilepsia 46 (2005) 31-41
12. Elger C.E., Brodie M.J., Anhut H., Lee C.M., and Barrett J.A. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study. Epilepsia 46 (2005) 1926-1936
13. Yamauchi T., Kaneko S., Yagi K., and Sase S. Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry Clin Neurosci 60 (2006) 507-515
14. Tsai J.J., Yen D.J., Hsih M.S., Chen S.S., Hiersemenzel R., Edrich P., et al. Efficacy and safety of levetiracetam (up to 2000 mg/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study. Epilepsia 47 (2006) 72-81
15. Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to antiepileptic drugs: a follow-up study of 355 patients with chronic antiepileptic drug treatment. Epilepsia 29 (1988) 787-793
16. Wong I.C.K., and Lhatoo S.D. Adverse reactions to new anticonvulsant drugs. Drug Saf 23 (2000) 35-56
17. Zaccara G., Cincotta M., Borgheresi A., and Balestrieri F. Adverse motor effects induced by antiepileptic drugs. Epileptic Disord 6 (2004) 153-168
18. Review Manager (RevMan) [Computer program]. Version 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2003.
19. Higgins J.P.T., Thompson S.G., Deeks J.J., and Altman D.G. Measuring inconsistency in meta-analyses. Br Med J 327 (2003) 557-560
20. Schlesselman X. Case-Control Studies (1982), Oxford University Press, New York pp. 203-206
21. Sivenius J., Kalviainen R., Ylinen A., and Riekkinen P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 32 (1991) 539-542
22. The US Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 43 (1993) 2292-2298
23. Anhut H., Ashman P., Feuerstein T.J., Sauermann W., Saunders M., and Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 35 (1994) 795-801
24. Chadwick D., Leiderman D.B., Sauermann W., Alexander J., and Garofalo E. Gabapentin in generalized seizures. Epilepsy Res 25 (1996) 191-197
25. Jawad S., Richens A., Goodwin G., and Yuen W.C. Controlled trial of lamotrigine for refractory partial seizures. Epilepsia 30 (1989) 356-363
26. Loiseau P., Yuen A.W., Duche B., Menager T., and Arne-Bes M.C. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 7 (1990) 136-145
27. Sander J.W., Patsalos P.N., Oxley J.R., Hamilton M.J., and Yuen W.C. A randomised double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 6 (1990) 221-226
28. Matsuo F., Bergen D., Faught E., Messenheimer J.A., Dren A.T., Rudd G.D., et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. U.S. Lamotrigine Protocol 0. 5 Clinical Trial Group. Neurology 43 (1993) 2284-2291
29. Schapel G.J., Beran R.G., Vajda F.J., Berkovic S.F., Mashford M.L., Dunagan F.M., et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neurol Neurosurg Psychiatry 56 (1993) 448-453
30. Smith D., Baker G., Davies G., Dewey M., and Chadwick D.W. Outcomes of add-on treatment with lamotrigine in partial epilepsy. Epilepsia 34 (1993) 312-322
31. Messenheimer J., Ramsay R.E., Willmore L.J., Leroy R.F., Zielinski J.J., Mattson R., et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 35 (1994) 113-121
32. Boas J., Dam M., Friis M.L., Kristensen O., Pedersen B., and Gallagher J. Controlled trial of lamotrigine (Lamictal) for treatment-resistant partial seizures. Acta Neurol Scand 94 (1996) 247-252
33. Beran R.G., Berkovic S.F., Dunagan F.M., Vajda F.J., Danta G., Black A.B., et al. Double-blind, placebo-controlled, crossover study of lamotrigine in treatment-resistant generalised epilepsy. Epilepsia 39 (1998) 1329-1333
34. Betts T., Waegemans T., and Crawford P. A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy. Seizure 9 (2000) 80-87
35. Ben-Menachem E., and Falter U. Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 41 (2000) 1276-1283
36. Cereghino J.J., Biton V., Abou-Khalil B., Dreifuss F., Gauer L.J., and Leppik I. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 55 (2000) 236-242
37. Shorvon S.D., Lowenthal A., Janz D., Bielen E., and Loiseau P. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group. Epilepsia 41 (2000) 1179-1186
38. Barcs G., Walker E.B., Elger C.E., Scaramelli A., Stefan H., Sturm Y., et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 41 (2000) 1597-1607
39. Kalviainen R., Brodie M.J., Duncan J., Chadwick D., Edwards D., and Lyby K. A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures. Northern European Tiagabine Study Group. Epilepsy Res 30 (1998) 31-40
40. Ben-Menachem E., Henriksen O., Dam M., Mikkelsen M., Schmidt D., Reid, et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 37 (1996) 539-543
41. Faught E., Wilder B.J., Ramsay R.E., Reife R.A., Kramer L.D., Pledger G.W., et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Topiramate YD Study Group. Neurology 46 (1996) 1684-1690
42. Privitera M., Fincham R., Penry J., Reife R., Kramer L., Pledger G., et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Topiramate YE Study Group. Neurology 46 (1996) 1678-1683
43. Sharief M., Viteri C., Ben-Menachem E., Weber M., Reife R., Pledger G., et al. Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Res 25 (1996) 217-224
44. Tassinari C.A., Michelucci R., Chauvel P., Chodkiewicz J., Shorvon S., Henriksen O., et al. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 37 (1996) 763-768
45. Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Epilepsia 40 (1999) 1767-1774
46. Yen D.J., Yu H.Y., Guo Y.C., Chen C., Yiu C.H., and Su M.S. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 41 (2000) 1162-1166
47. Schmidt D., Jacob R., Loiseau P., Deisenhammer E., Klinger D., Despland A., et al. Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res 15 (1993) 67-73
48. Faught E., Ayala R., Montouris G.G., Leppik I.E., and Zonisamide 922 Trial Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology 57 (2001) 1774-1779
49. Sachdeo R.C., Leroy R.F., Krauss G.L., Drake Jr. M.E., Green P.M., Leppik I.E., et al. Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group. Arch Neurol 54 (1997) 595-601
50. Uthman B.M., Rowan A.J., Ahmann P.A., Leppik I.E., Schachter S.C., Sommerville K.W., et al. Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial. Arch Neurol 55 (1998) 56-62
51. Sander J.W. Using topiramate in patients with epilepsy: practical aspects. Can J Neurol Sci 25 (1998) S16-S18
52. Goa K.L., Ross S.R., and Chrisp P. Lamotrigine. A review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 46 (1993) 152-176
53. Farwell J.R., Lee Y.J., Hirtz D.G., Sulzbacher S.I., Ellenberg J.H., and Nelson K.B. Henobarbital for febrile seizures. Effects on intelligence and on seizure recurrence. N Engl J Med 322 (1990) 364-369
54. Wong J.C.K., and Lhatoo S.D. Adverse reactions to new anticonvulsant drugs. Drug Saf 23 (2000) 35-56
55. Meeusen R., Watson P., Hasegawa H., Roelands B., and Piacentini M.F. Central fatigue: the serotonin hypothesis and beyond. Sports Med 36 (2006) 881-909
56. Vajda F.J.E. Gabapentin. Chemistry, biotransformation, pharmacokinetics, and interactions. In: Levy R.H., Mattson R.H., Meldrum B.S., and Perucca E. (Eds). Antiepileptic Drugs. 5th ed. (2002), Lippincott Williams & Wilkins, Philadelphia 335-339